US OptionsDetailed Quotes
MESO240816C8000
- 0.75
- +0.34+82.93%
15min DelayClose Jul 23 15:59 ET
0.85High0.75Low
0.85Open0.41Pre Close6 Volume45 Open Interest8.00Strike Price460.00Turnover71.08%IV5.80%PremiumAug 16, 2024Expiry Date0.27Intrinsic Value100Multiplier23DDays to Expiry0.48Extrinsic Value100Contract SizeAmericanOptions Type0.6149Delta0.2537Gamma11.03Leverage Ratio-0.0128Theta0.0028Rho6.78Eff Leverage0.0081Vega
Mesoblast Stock Discussion
Sign in to post a comment
$Mesoblast(MESO.US$ Mesoblast (MESO) has released an update. Mesoblast Limited has resubmitted a Biologics License Application (BLA) to the FDA for Ryoncil®, aiming to treat children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD). The resubmission, buoyed by promising Phase 3 study results demonstrating significant survival benefits, could meet an urgent need for effective treatment in this patient group, as current survival outcomes are poor and no FDA-approved treatm...
2
$Mesoblast(MESO.US$ which is developing off-the-shelf cellular medicines for life-threatening inflammatory conditions, is planning to file a Biologics License Application for Ryoncil with the FDA next week.
2
2
$Mesoblast(MESO.US$ .write time to sell !! drop since form monday
$Mesoblast(MESO.US$ ..Even drop no one willing to sell!!!!
1
$Mesoblast(MESO.US$ my cards never lie! But looking at the head guy for yhis company and all his achievements it was a no brainer! Had no doubts here! Hope that guy stayed in!
$Mesoblast(MESO.US$ Mesoblast Nears FDA Approval for Key Therapies
Mesoblast (MESO) has released an update.
Mesoblast Limited has reported significant progress in its discussions with the FDA, receiving guidance on licensure paths for its innovative therapies, remestemcel-L for pediatric graft versus host disease, and rexlemestrocel-L for end-stage heart failure. The company is poised to resubmit its Biologics License Application for remestemcel-L and seeks an accelerated approval for ...
Mesoblast (MESO) has released an update.
Mesoblast Limited has reported significant progress in its discussions with the FDA, receiving guidance on licensure paths for its innovative therapies, remestemcel-L for pediatric graft versus host disease, and rexlemestrocel-L for end-stage heart failure. The company is poised to resubmit its Biologics License Application for remestemcel-L and seeks an accelerated approval for ...
2
$Mesoblast(MESO.US$ .. may chance pass to 8plus
$Mesoblast(MESO.US$ .. No chnace to turn to green by this week.
2
3
No comment yet
101674396 : Hold or sell?
TrytosaveabitOP 101674396: Sorry I don’t give buy/sell advice! There’s no way for me to know others risk tolerance or the type of trade they are doing! I will say that I am still bullish on this! NFA JMO! GL